Novocure Receives Not Approvable Letter for Optune Mya Brain Metastases Therapy
Novocure received a Not Approvable Letter from the FDA for its Optune Mya PMA application for brain metastases following radiation, citing uncertainty regarding clinical benefits. The company is evaluating feedback to determine potential paths to approval without further studies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed